/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Lyra Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$4.16 0.0449(4.49%) LYRA at 04 Dec 2025 04:38 PM Biotechnology
Lowest Today 4
Highest Today 4.26
Today’s Open 4.075
Prev. Close 4.01
52 Week High 34.00
52 Week Low 2.84
Day’s Range: Low 4 High 4.26
52-Week Range: Low 2.84 High 34.00
1 day return -
1 Week return +15.12
1 month return -25.13
3 month return -39.86
6 month return -81.93
1 year return +1865.56
3 year return +20.88
5 year return -66.82
10 year return -

Institutional Holdings

Perceptive Advisors LLC 15.52

Sabby Management LLC 7.65

Vanguard Group Inc 1.77

Bank of America Corp 1.74

Ikarian Capital, LLC 1.29

Vanguard Total Stock Mkt Idx Inv 1.18

Geode Capital Management, LLC 0.67

State Of Wisconsin Investment Board 0.64

Goldman Sachs Group Inc 0.45

Vanguard Institutional Extnd Mkt Idx Tr 0.38

Fidelity Extended Market Index 0.33

Morgan Stanley - Brokerage Accounts 0.13

Dimensional US Small Cap ETF 0.13

Rhumbline Advisers 0.11

FMR Inc 0.11

BlackRock Inc 0.10

Spartan Total Market Index Pool G 0.10

Acadian Asset Management LLC 0.10

Tower Research Capital LLC 0.09

Spartan Extended Market Index Pool F 0.09

Extended Equity Market Fund K 0.08

DFA US Core Equity 2 I 0.08

Fidelity Series Total Market Index 0.08

State Street Russell 2000 Value CIT 0.07

Fidelity Total Market Index 0.07

Royal Bank of Canada 0.07

DFA US Social Core Equity 2 Portfolio 0.06

Citigroup Inc 0.05

NT Col R2000 Val Idx Fd -DC -L -TierFour 0.04

NT Ext Equity Mkt Idx Fd - NL 0.04

Northern Trust Extended Eq Market Idx 0.04

NT Ext Equity Mkt Idx Fd - L 0.04

Valley National Advisers Inc 0.03

Signature Resources Capital Management, LLC 0.02

Blackstone Alternative Multi-Strategy I 0.01

NT Ext Eq Mkt Indx Fd DC Lend T3 0.01

SSgA U.S. Total Market Index Strategy 0.01

Amalgamated Financial Corp 0.00

SIMPLEX TRADING, LLC 0.00

ProFunds UltraSmall Cap Inv 0.00

Market Status

Strong Buy: 0

Buy: 0

Hold: 4

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 7.12 M

PB Ratio 7.0969

PE Ratio 0.0

Enterprise Value 15.87 M

Total Assets 66.35 M

Volume 48758

Company Financials

Annual Revenue FY23:1423000 1.4M, FY22:1363000 1.4M, FY21:285000 0.3M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:1363000 1.4M, FY21:285000 0.3M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-61759000 -61.8M, FY22:-55278000 -55.3M, FY21:-42410000 -42.4M, FY20:-22045000 -22.0M, FY19:-16093000 -16.1M

Quarterly Revenue Q3/2025:25000 0.0M, Q2/2025:183000 0.2M, Q1/2025:183000 0.2M, Q3/2024:195000 0.2M, Q2/2024:598000 0.6M

Quarterly Profit Q3/2025:-75000 -0.1M, Q2/2025:-17000 -0.0M, Q1/2025:183000 0.2M, Q3/2024:195000 0.2M, Q2/2024:-12666000 -12.7M

Quarterly Net worth Q3/2025:-5984000 -6.0M, Q2/2025:-7437000 -7.4M, Q1/2025:-8547000 -8.5M, Q3/2024:-11873000 -11.9M, Q2/2024:-48131000 -48.1M

Fund house & investment objective

Company Information Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Organisation Biotechnology

Employees 30

Industry Biotechnology

CEO Dr. Maria Palasis Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow